Your browser doesn't support javascript.
loading
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.
Al Olama, Ali Amin; Kote-Jarai, Zsofia; Berndt, Sonja I; Conti, David V; Schumacher, Fredrick; Han, Ying; Benlloch, Sara; Hazelett, Dennis J; Wang, Zhaoming; Saunders, Ed; Leongamornlert, Daniel; Lindstrom, Sara; Jugurnauth-Little, Sara; Dadaev, Tokhir; Tymrakiewicz, Malgorzata; Stram, Daniel O; Rand, Kristin; Wan, Peggy; Stram, Alex; Sheng, Xin; Pooler, Loreall C; Park, Karen; Xia, Lucy; Tyrer, Jonathan; Kolonel, Laurence N; Le Marchand, Loic; Hoover, Robert N; Machiela, Mitchell J; Yeager, Merideth; Burdette, Laurie; Chung, Charles C; Hutchinson, Amy; Yu, Kai; Goh, Chee; Ahmed, Mahbubl; Govindasami, Koveela; Guy, Michelle; Tammela, Teuvo L J; Auvinen, Anssi; Wahlfors, Tiina; Schleutker, Johanna; Visakorpi, Tapio; Leinonen, Katri A; Xu, Jianfeng; Aly, Markus; Donovan, Jenny; Travis, Ruth C; Key, Tim J; Siddiq, Afshan; Canzian, Federico.
Afiliação
  • Al Olama AA; 1] Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. [2].
  • Kote-Jarai Z; 1] Institute of Cancer Research, London, UK. [2].
  • Berndt SI; Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA.
  • Conti DV; 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
  • Schumacher F; 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
  • Han Y; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Benlloch S; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Hazelett DJ; 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
  • Wang Z; 1] Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA. [2] Cancer Genomics Research Laboratory, National Cancer Institute, Division of Cancer Epidemiology and Genetics, SAIC-Frederick, Inc., Frederick, Maryland, USA.
  • Saunders E; Institute of Cancer Research, London, UK.
  • Leongamornlert D; Institute of Cancer Research, London, UK.
  • Lindstrom S; Program in Genetic Epidemiology and Statistical Genetics, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA.
  • Jugurnauth-Little S; Institute of Cancer Research, London, UK.
  • Dadaev T; Institute of Cancer Research, London, UK.
  • Tymrakiewicz M; Institute of Cancer Research, London, UK.
  • Stram DO; 1] Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. [2] Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA.
  • Rand K; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Wan P; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Stram A; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Sheng X; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Pooler LC; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Park K; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Xia L; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Tyrer J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Kolonel LN; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
  • Le Marchand L; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
  • Hoover RN; Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA.
  • Machiela MJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA.
  • Yeager M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA.
  • Burdette L; Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA.
  • Chung CC; Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA.
  • Hutchinson A; Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA.
  • Yu K; Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institute of Health, Bethesda, Maryland, USA.
  • Goh C; Institute of Cancer Research, London, UK.
  • Ahmed M; Institute of Cancer Research, London, UK.
  • Govindasami K; Institute of Cancer Research, London, UK.
  • Guy M; Institute of Cancer Research, London, UK.
  • Tammela TL; Department of Urology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland.
  • Auvinen A; Department of Epidemiology, School of Health Sciences, University of Tampere, Tampere, Finland.
  • Wahlfors T; BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland.
  • Schleutker J; 1] BioMediTech, University of Tampere and FimLab Laboratories, Tampere, Finland. [2] Department of Medical Biochemistry, Institute of Biomedicine, University of Turku, Turku, Finland.
  • Visakorpi T; Institute of Biomedical Technology/BioMediTech, University of Tampere and Tampere University Hospital, Tampere, Finland.
  • Leinonen KA; Institute of Biomedical Technology/BioMediTech, University of Tampere and Tampere University Hospital, Tampere, Finland.
  • Xu J; Center for Cancer Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Aly M; 1] Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. [2] Department of Clinical Sciences at Danderyds Hospital, Stockholm, Sweden.
  • Donovan J; School of Social and Community Medicine, University of Bristol, Bristol, UK.
  • Travis RC; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Key TJ; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
  • Siddiq A; Department of Genomics of Common Disease, School of Public Health, Imperial College London, London, UK.
  • Canzian F; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nat Genet ; 46(10): 1103-9, 2014 Oct.
Article em En | MEDLINE | ID: mdl-25217961
ABSTRACT
Genome-wide association studies (GWAS) have identified 76 variants associated with prostate cancer risk predominantly in populations of European ancestry. To identify additional susceptibility loci for this common cancer, we conducted a meta-analysis of > 10 million SNPs in 43,303 prostate cancer cases and 43,737 controls from studies in populations of European, African, Japanese and Latino ancestry. Twenty-three new susceptibility loci were identified at association P < 5 × 10(-8); 15 variants were identified among men of European ancestry, 7 were identified in multi-ancestry analyses and 1 was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations. These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único / Loci Gênicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Predisposição Genética para Doença / Polimorfismo de Nucleotídeo Único / Loci Gênicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans / Male Idioma: En Ano de publicação: 2014 Tipo de documento: Article